SOLICITATION NOTICE
R -- Compile and analyze data on NF2 and Chrodoma Studies
- Notice Date
- 5/4/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70055-NV
- Response Due
- 5/14/2007
- Archive Date
- 5/29/2007
- Description
- National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis with Dilys Parry Ph.D., Bethesda, MD 20817, to provide medical geneticist services for a one year base period with one one-year option period. The supplies and services herein are commercial as described in FAR Part 2 and the supplies and services are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.501. The North American Industry Classification System Code is 541990 and the business size standard is $6.5. The Genetic Epidemiology Branch (GEB) of the Division of Cancer Epidemiology and Genetics conducts studies to evaluate the interaction of host and environmental factors in cancer causation. One of the cornerstones of this research is family studies: the interdisciplinary clinical, genetic, epidemiologic and laboratory evaluations of kindreds with or at high risk of specific cancers or tumors. These investigations have provided important insights into cancer etiology. Through them GEB has been able to map susceptibility genes for a number of different familial cancer and preneoplastic syndromes, and become involved in isolating the genes, defining their functions and evaluating their roles in nonfamilial cancers in specific populations. By expanding the number of kindreds studied with different cancer and following them over several decades, GEB has been able to demonstrate the presence of genetic heterogeneity in some cancer syndromes, assess the occurrence of genotype-phenotype correlations, define the natural history, quantify prospective risks of cancers in members of some types of families, evaluate gene-gene or gene-environmental interactions, and integrate environmental risk factors into risk analyses. The familial cancer syndromes studied by the branch include neurofibromatosis 2 (NF2) and familial chordoma. The contractor shall perform the following tasks during the period covered by this procurement. 1) The contractor shall provide recommendation and guidance on conducting the assembly and analysis of data and preparation of a manuscript on the long term follow-up of NIH NF2 patients. a) The contractor shall review the medical/research/vital records of each NF2 patient for completeness and provide guidance and recommendations for the retrieval of missing records; b) The contractor shall arrange for NF2 mutation testing to be carried out on DNA from patients for whom no NF2 mutation had been identified previously; c) The contractor shall review the medical/research/vital records of each NF2 patient and prepare tabulations of clinical parameters, treatment types and outcomes by age, gender, family and mutation type; d) The contractor shall review the results of NIH clinical testing (audiology, ophthalmology, MR imaging results) on the NF2 patients with clinical experts at NIH; e) The contractor shall prepare a manuscript describing the results and conclusions of the long term follow-up for review by the project officer; f) The contractor shall prepare oral and/or poster presentations of results of the long term follow-up. 2) The contractor shall provide recommendation and guidance on conducting the assembly and analysis of clinical data on the NIH chordoma families. a) The contractor shall review the medical/research/vital records of each chordoma patient and examined family members for completeness and provide guidance and recommendations for the retrieval of missing records; b) The contractor shall review the medical/research/vital records of each chordoma patient and prepare tabulations of clinical parameters, treatment types and outcomes by age, gender, and family; c) The contractor shall review the results of outside and NIH neuroaxis imaging studies on the chordoma patients and examined family members with neuroradiologists at NIH; d) The contractor shall review the medical literature on familial chordoma; e) The contractor shall prepare a manuscript describing the results and conclusions of the clinical evaluation of chordoma families studied at NIH and the chordoma families reported in the medical literature for review by GEB collaborators and the project officer; f) The contractor shall prepare oral and/or poster presentations of results of the review of familial chordoma. 3) The contractor shall provide recommendations and guidance on gene mapping and other types of molecular studies on specimens from NIH chordoma families. a) The contractor shall provide guidance and recommendations for genotyping studies to be carried out on lymphocyte/buccal cell DNA from chordoma patients and examined family members; b) The contractor shall provide guidance and recommendations for molecular studies to be carried out on DNA from lymphocytes, buccal cells and tumors from familial chordoma patients; c) The contractor shall provide guidance and recommendations on the development of manuscripts on gene mapping and other molecular studies of familial chordoma. 4) The contractor shall provide recommendations and guidance on the design and conduct of studies to identify new multiplex chordoma families. a) The contractor shall make recommendations and provide guidance on the continuation of the collaboration with Massachusetts General Hospital and possible expansion to include individuals diagnosed with chordoma > age 18 years. b) The contractor shall make recommendations and provide guidance on the development of new collaborations with radiation oncologists and/or skull base neurosurgeons within the USA and countries outside of the USA to identify new chordoma families. c) The contractor shall provide recommendations and guidance for the clinical evaluation of individuals with chordoma and/or related tumors and their blood relatives from newly identified chordoma families. 5) The contractor shall provide recommendations and guidance to support GEB family and gene mapping studies. Contractor Requirements: The contractor shall be a geneticist with board certification as a Ph.D medical geneticist and at least 20 years of experience in the ascertainment, clinical evaluation and counseling of individuals with NF2 and their close relatives and 10 years of experience in the ascertainment, clinical evaluation and counseling of individuals with familial chordoma and their close relatives. The contractor must have at least 20 years of experience in leading and guiding clinical and gene mapping studies of families with preneoplastic disorders. Dr. Parry has provided medical geneticist support for high quality clinical and gene mapping studies of patients and families at increased risk for cancer for the DCEG for the past 30 years. She had conducted research directed towards delineating syndromes and mapping genes that predispose to cancer. Her role in these studies included identifying patients and families of interest, obtaining and interpreting individual and family medical histories, delineating and arranging appropriate diagnostic studies and the procurement of research specimens, directing and participating in the clinical evaluation of family members, providing genetic counseling to affected and at risk family members and analyzing the data from the studies and preparing manuscripts for publication. Over a period of almost 20 years, Dr. Parry directed the NCI studies that lead to the identification and cloning of the gene for neurofibromatosis 2, delineated the spectrum of clinical manifestations associated with NF2 and elucidated correlations between the specific types of mutations in the NF2 gene and clinical findings. As a result of these activities she was named NF Scholar of 2002 by Neurofibromatosis Inc., a national support group for patients with neurofibromatosis and their family members. Over the last 10 years, Dr. Parry directed studies of familial chordoma that lead to the identification and clinical evaluation of 6 chordoma families and resulted in mapping a gene for the disorder to chromosome 7q. Because of her expertise on familial chordoma she has been invited to be on the organizing committee for the NIH supported first international workshop on chordoma research. Dr. Parry?s working interactions with the NCI and extramural researchers on the NF2 and familial chordoma projects, her previous involvement in and understanding of the research and her in depth knowledge of clinical aspects of neurofibromatosis 2 and familial chordoma are unique assets that no other contractor could provide. In addition, she is currently approved by the NIH Clinical Center to be involved in patient care there as a medical geneticist. Therefore, there is no other medical geneticist who possesses the experience, expertise and detailed knowledge of these studies needed to allow him/her to immediately undertake the tasks covered by this procurement and conduct these efforts in a timely fashion. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 PM EDT May 14, 2007. Faxed and emailed capability statements are NOT authorized. Questions must be submitted in writing to Deborah Moore, Contract Specialist, at dm170b@nih.gov or faxed to 301-402-4513. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please cite reference number NCI-70050-NV on all correspondence.
- Record
- SN01287690-W 20070506/070504220352 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |